Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test
Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is...
Source: finanznachrichten.de
